Waksal promises big things for his new drug firm

With his five-year prison stint for insider trading receding in the background, Sam Waksal (photo) is back in visionary mode, telling New York Times writer Andrew Pollack that his new biotech company will be bigger and better than ImClone ever was. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.